The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shchulkin A.V.

Pavlov Ryazan State Medical University

Kazakhmedov E.R.

Peoples’ Friendship University of Russia

Galochkin S.A.

Peoples’ Friendship University of Russia

Tolkacheva V.V.

Peoples’ Friendship University of Russia

Kobalava Z.D.

Peoples’ Friendship University of Russia

Effects of mexidol in patients with chronic brain ischemia and chronic heart failure (II-III functional class)

Authors:

Shchulkin A.V., Kazakhmedov E.R., Galochkin S.A., Tolkacheva V.V., Kobalava Z.D.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5): 427‑434

DOI: 10.17116/kardio202013051427

Read: 8865 times

Contact the author
Table of contents

EFFECTS OF MEXIDOL IN PATIENTS WITH CHRONIC BRAIN ISCHEMIA AND CHRONIC HEART FAILURE (II-III FUNCTIONAL CLASS)
EFFECTS OF MEXIDOL IN PATIENTS WITH CHRONIC BRAIN ISCHEMIA AND CHRONIC HEART FAILURE (II-III FUNCTIONAL CLASS)

To cite this article:

Shchulkin AV, Kazakhmedov ER, Galochkin SA, Tolkacheva VV, Kobalava ZD. Effects of mexidol in patients with chronic brain ischemia and chronic heart failure (II-III functional class). Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5):427‑434. (In Russ.)
https://doi.org/10.17116/kardio202013051427

 
Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Opti­mal cardioplegia for coro­nary artery bypass grafting in patients with heart failure: a randomized study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):405-411
The impact of Mexi­dol on improving quality of life para­meters and functional kidney status as part of complex therapy for cognitive impairments in como­rbid patients with microalbuminuria against the background of arte­rial hype­rtension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Cardiogenic deme­ntia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):43-49
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Oxidative stress and dyna­mics of its patterns following therapeutic physical factors in complex therapy of vaso­motor rhinitis. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):12-21
Visceral obesity is a reve­rsible factor in pathogenesis of major cardiovascular diseases. Russian Cardiology Bulletin. 2025;(3):11-16
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Study of drug-drug inte­ractions between Mexi­dol and thro­mbolytic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):139-144
Abstract:

AIM

To study the effect of mexidol on N-terminal pro B-type natriuretic peptide (NT-proBNP), markers of oxidative stress, inflammatory reaction and endothelial dysfunction in patients with chronic brain ischemia and chronic heart failure II-III NYHA functional class while 13 weeks of sequential intravenous and oral therapy with mexidol and standard therapy.

MATERIAL AND METHODS

Study included 44 patients with chronic brain ischemia and chronic heart failure II-III NYHA functional class with ejection fraction less 50%. Mean age: 65.5±11.8 years, 75% men. 21 patients of group mexidol plus standard therapy of chronic heart failure received mexidol at a dose of 1000 mg/day by intravenous infusion for 7 days followed by oral doses of 250 mg three times a day for twelve weeks, 23 patients received standard therapy. 34 patients completed the trial, in 10 patient the final visit was performed as telephone call due to epidemiologic situation. Concentration of N-terminal pro B-type natriuretic peptide (NT-proBNP), markers of oxidative stress (malonic dialdehyde (MDA), superoxide dismutase (SOD)), inflammatory reaction (C-reactive protein (CRP), tumor necrosis factor α (TNFα)), homocysteine and cystatin C were examined in blinded manner in all patients initially, on day 7 and week 13.

RESULTS

Statistically significant more prominent decrease of NT-proBNP, MDA, CRP and TNFα and increase of SOD by day 7 and week 13 were observed in patients treated with mexidol along with standard therapy in comparison with group treated with standard therapy.

CONCLUSION

Mexidol added to standard therapy of patients with chronic brain ischemia and chronic heart failure II-III functional class decreases concentration of NT-proBNP, has proven antioxidant activity, decreases the degree of inflammatory reaction, slows down the increase of homocysteine, does not influence the kidney function (by measurement of cystatin C).

Keywords:

chronic brain ischemia
heart failure
oxidative stress
antioxidants
N-terminal pro B-type natriuretic peptide (NT-proBNP)
malonic dialdehyde
superoxide dismutase
CRP
TNFα
ethyl-methyl-hydroxipyridin succinate
mexidol

Authors:

Shchulkin A.V.

Pavlov Ryazan State Medical University

Kazakhmedov E.R.

Peoples’ Friendship University of Russia

Galochkin S.A.

Peoples’ Friendship University of Russia

Tolkacheva V.V.

Peoples’ Friendship University of Russia

Kobalava Z.D.

Peoples’ Friendship University of Russia

Received:

21.08.2020

Accepted:

10.09.2020

Close metadata

References:

  1. Katz SD, Hryniewicz K, Hriljac I, et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation. 2005;111:310-314.  https://doi.org/10.1161/01.cir.0000153349.77489
  2. Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circulation J. 2009; 3:411-415.  https://doi.org/10.1253/circj.cj-08-1102
  3. Romuk E, Wojciechowska C, Jacheć W, et al. Comparison of Oxidative Stress Parameters in Heart Failure Patients Depending on Ischaemic or Nonischaemic Aetiology. Oxidative Medicine and Cellular Longevity. 2019;Article ID 7156038. https://doi.org/10.1155/2019/7156038
  4. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today. 2006;11-12:524-526.  https://doi.org/10.1016/j.drudis.2006.04.003
  5. Drapkina OM, Palatkina LO. New emphases on the study of the pathogenesis of chronic heart failure with preserved ejection fraction: focus on inflammatory markers. Rational Pharmacotherapy in Cardiology. 2014;10(3):317-321. (In Russ.). https://doi.org/10.20996/1819-6446-2014-10-3-317-321
  6. Petersen JW, Felker GM. Inflammatory Biomarkers in Heart Failure. Congestive Heart Failure. 2006;12(6):324-328.  https://doi.org/10.1111/j.1527-5299.2006.05595
  7. Palatkina LO, Korneeva ON, Drapkina OM. Oxidative stress, its role in the pathogenesis of chronic heart failure, and potential methods of correction. Cardiovascular Therapy and Prevention. 2012;11(6):91-94. (In Russ.). https://doi.org/10.15829/1728-8800-2012-6-91-94
  8. Arutyunov AG, Dragunov DO, Arutyunov GP, Rylova AK, Sokolova AV, Rylova NV. Prognostically significant clinical phenotypes of patients with circulatory decompensation in the Russian Federation. Russian Heart Failure Journal. 2015;16(5):270-278. (In Russ.).
  9. D’Elia E, Vaduganathan M, Gori M, Gavazzi A. Role of biomarkers in cardiac structure phenotyping in heart failure with pre-served ejection fraction: critical appraisal and practical use. Eur J Heart Fail. 2015;17(12):1231-1239. https://doi.org/10.1002/ejhf.43
  10. Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019;119(4):115-124. (In Russ.). https://doi.org/10.17116/jnevro2019119041115
  11. Statsenko ME, Evtereva ED, Turkina SV, et al. New possibilities of mexicor in the treatment of chronic heart failure in patients with metabolic syndrome. Russian Journal of Cardiology 2010;6(86):28-33. (In Russ.). https://doi.org/10.15829/1560-4071-2010-6-28-33
  12. Sidorenko GI, Komissarova SM, Zolotukhina SF, Petrovskaya ME. The use of ethylmethylhydoxypyridine succinate in the treatment of patients with heart failure. Kardiologya. 2011;6:44-48. (In Russ.).
  13. Kostyuk VA, Potapovich AI, Kovaleva ZhV. Prostoj i chuvstvitel’nyj metod opredeleniya aktivnosti superoksiddismutazy, osnovannyj na reaktsii okisleniya kvertsitina. Voprosy meditsinskoj khimii. 1990;36(2):88-91. (In Russ.).
  14. Polunina EA, Voronina LP, Popov EA, Belyakova IS, Polunina OS, Tarasochkina DS. Prognostic algorithms for the progression of chronic heart failure depending on the clinical phenotype. Cardiovascular Therapy and Prevention. 2019;18(3):41-47. (In Russ.). https://doi.org/10.15829/1728-8800-2019-3-41-47
  15. Shchulkin AV. A modern concept of antihypoxic and antioxidant effects of mexidol. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018;12(2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
  16. Klinicheskie rekomendatsii OSSN — RKO — RNMOT. Serdechnaya nedostatochnost’: khronicheskaya (KhSN) i ostraya dekompensirovannaya (ODSN). Diagnostika, profilaktika i lechenie. 2018. (In Russ.). https://doi.org/10.18087/cardio.2475
  17. Ferreira JP, Duarte K, Graves TL, Zile MR, Abraham WT, Weaver FA, et al. Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. J Am Coll Cardiol. 2016;68(24):2690-2707. https://doi.org/10.1016/j.jacc.2016.09.936
  18. Shchulkin AV. Vliyanie meksidola na razvitie fenomena eksajtotoksichnosti nejronov in vitro. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2012;112(2):35-39. (In Russ.).
  19. D’Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A, Laviola L, Giorgino F. The role of oxidative stress in cardiac disease: from physiological response to injury factor. Oxidative Medicine and Cellular longevity. 2020. https://doi.org/10.1155/2020/5732956
  20. Price BR, Wilcock DM and Weekman EM Front. Aging Neurosci. 2018;10(10):350.  https://doi.org/10.3389/fnagi.2018.00350
  21. Naruszewicz M, Jankowska EA, Zymlinski R, Bukowska H, Millo B, Banasiak W, Ponikowski P. Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance — pilot study. Atherosclerosis. 2007;194:408-414.  https://doi.org/10.1016/j.atherosclerosis.2006.08.014
  22. Kasperczyk S, Dobrakowski M, Kasperczyk A, et al. Effect of N-acetylcysteine administration on homocysteine level, oxidative damage to proteins, and levels of iron (Fe) and Fe-related proteins in lead-exposed workers. Toxicol Ind Health. 2016;32(9):1607-1618. https://doi.org/10.1177/0748233715571152
  23. Yin W-H, Chen J-W, Jen H-L, Chiang M-C, Huang W-P, Feng A-N, Lin S-J. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. American Heart Journal. 2004;147(5):931-938.  https://doi.org/10.1016/j.ahj.2003.11.021
  24. Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S, Matsumori A. Serial circulating concentra- tions of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clinical Cardiology. 1999;22:811-813.  https://doi.org/10.1002/clc.4960221211
  25. Yamauchi-Takihara K, Ihara Y, Ogata A, Yoshizaki K, Azuma J, Kishimoto T. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520-1524. https://doi.org/10.1161/01.CIR.91.5.1520
  26. Ferrari R. The role of TNF in cardiovascular disease. Pharmacological Research. 1999;40(2):97-105.  https://doi.org/10.1006/phrs.1998.0463
  27. Kirova YuI, Shakova FM, Germanova EL, Romanova GA, Voronina TA. Vliyanie Meksidola na tserebral’nyj mitokhondriogenez v molodom vozraste i pri starenii. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2020;120(1):62-69. (In Russ.). https://doi.org/10.17116/jnevro202012001162
  28. Ferguson TW, Komenda P, Tangri N. Cystatin C as a Biomarker for Estimating Glomerular Filtration Rate. Curr Opin Nephrol Hypertens. 2015;24(3):295-300.  https://doi.org/10.1097/MNH.0000000000000115
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.